Skip to content
All industries
Industry

Healthcare and Life Sciences in Japan

Approval and reimbursement are two separate policy processes in Japan, and the second, the NHI price and its biennial cuts, decides the commercial outcome.

Request a Japan issues briefing Where to engage
Policy environment

How Healthcare and life sciences policy is made in Japan.

Market access in Japan runs through the Pharmaceuticals and Medical Devices Agency for review and the Ministry of Health, Labour and Welfare for approval, then through Chuikyo, the Central Social Insurance Medical Council, for the NHI price. Prices are cut on a regular cycle and the rules for premiums, cost-effectiveness assessment, and repricing are argued every year in the run-up to the fiscal revision.

The current agenda includes the drug-lag and drug-loss debate, reforms to encourage earlier launches, the expansion of cost-effectiveness evaluation, regulation of programmed medical devices and digital health, and tightening of health-food rules after recent safety incidents. Industry associations, both Japanese and foreign, are the main channel into these decisions.

Key institutions

Who decides.

01

Ministry of Health, Labour and Welfare (厚生労働省)

Approval, pricing policy, health-food and cosmetics regulation, and the pharmaceutical affairs councils.

02

PMDA (医薬品医療機器総合機構)

Scientific review and consultation for drugs, devices, and regenerative products.

03

Chuikyo (中央社会保険医療協議会)

NHI price listing, premiums, cost-effectiveness assessment, and revision rules.

04

Ministry of Finance and the fiscal councils

Where the pressure for price cuts originates, through the annual budget process.

05

Consumer Affairs Agency (消費者庁)

Health claims, foods with function claims, and labeling.

06

Industry associations (JPMA, PhRMA Japan, EFPIA Japan, AMDD, JFRL)

The channels through which pricing and approval policy positions are formed and presented.

Regulatory and political risks

What can go wrong.

  • Repricing and premium rules changed at a fiscal revision without effective industry input.

  • Cost-effectiveness assessment expanded to cover your product category.

  • Delays or conditions in approval that reflect policy priorities rather than the science.

  • Health-food and claim rules tightened after safety incidents elsewhere in the sector.

Where to engage

Engagement needs.

  1. 01

    Work through the association channels into Chuikyo and MHLW, with evidence framed around access, innovation, and fiscal sustainability.

  2. 02

    Track the pharmaceutical affairs councils, the drug-lag working groups, and the MOF fiscal councils to anticipate the revision agenda.

  3. 03

    Engage the LDP health policy divisions where the political trade-offs on pricing are made.

  4. 04

    Prepare for the fiscal cycle: positions need to be in place by summer for the following April.

Relevant services

How we work in this sector.

All services

Policy Monitoring and Analysis

Our own intelligence platform, read by analysts. Developments before they become news.

See how we work

Stakeholder Mapping and Engagement

A precise picture of allies, pressure points, and relationships worth investing in.

See how we work

Government Relations and Advocacy

On-the-ground relationships combined with evidence-based advocacy.

See how we work
Current analysis

Our published work on Healthcare and life sciences.

All analysis

Bringing a Medical Device or Drug to Market in Japan (2026 Guide)

Classification decides your route, and the route decides your schedule. Third-party certification runs 90 days; MHLW approval runs 10 months. The licences, the foreign manufacturer step, and the published processing times for every stage.

Read

Drug Pricing in Japan: How the NHI Price (薬価) Is Set, and Then Cut

Approval gets a drug into Japan; the NHI price decides whether the market is worth having. Japan sets one reimbursement price per drug, calculates it by comparator or cost, adjusts it against foreign prices, and then revises it downward every year for the life of the product. A map of how the number is set, why it only falls, and where the rules are actually decided.

Read

PMDA Japan: What the Pharmaceuticals and Medical Devices Agency Does

The PMDA (Pharmaceuticals and Medical Devices Agency) is Japan's regulator for drugs and medical devices: clinical review, post-market safety, and relief for adverse effects. How it works, how it differs from the FDA, and why MHLW, not PMDA, signs the approval.

Read

Health Food and Supplement Registration in Japan (2026 Guide)

There is no single supplement registration in Japan. What applies is the MHLW import notification, the Consumer Affairs Agency's Foods with Function Claims notification, or Tokuho approval, depending on classification and claims. A 2026 step-by-step guide to registering and importing health foods and dietary supplements, including Japanese labeling and Organic JAS.

Read

Cosmetic Product Registration in Japan: 2026 Import Guide

There is no single cosmetic product registration in Japan. What applies under the PMD Act is a licensed Japan-side marketing authorization holder, a marketing notification for each cosmetic, and a separate approval for quasi-drugs. A 2026 guide to registering and importing cosmetics and quasi-drugs: classification, licensing, ingredient review, labeling, and claims.

Read

Consumer Affairs Agency Japan (CAA): What It Regulates

Japan's Consumer Affairs Agency (CAA, 消費者庁) sets the rules on food labeling, health claims, advertising, and digital consumer protection. What it regulates, its 2026 priorities, and what foreign brands need to get right.

Read
Complimentary 30-minute briefing

Request a briefing on Japan’s healthcare policy environment.

Tell us your product category and where you are in the approval and pricing cycle. A principal will brief you on the councils and timelines that apply.

Request a Japan issues briefing Or discuss your Japan priorities

Your inquiry will be reviewed personally by Mickey or Kelly Langley. We normally respond within one business day.

Next industry
Manufacturing and Economic Security